BECAUSE TIME MATTERS IDYLLATM ctEGFR MUTATION ASSAY





FAST AND EASY CLEGFR TESTING



COMPREHENSIVE ASSAY

• Covers 49 mutations including insertions and deletions in exon 18, 19, 20 and 21 in the *EGFR* gene



EASE OF USE

- Fully automated sample-to-result process
- Walk-away system
- All PCR reagents integrated in a single cartridge
- Contamination-controlled design



FAST RESULTS

- ± 2 minutes hands-on time
- Short turnaround time ± 160 minutes from sample to result



SUITABLE FOR ANY LAB

- No special expertise required
- Minimal infrastructure needed



LIQUID BIOPSY

• Directly from 2 ml of plasma



ACCESSIBLE

- Access on demand
- No need for pre-processing or batching



THE IDYLLA™ ctEGFR MUTATION ASSAY SHOWS HIGH CONCORDANCE TO NGS¹

The Idylla™ ctEGFR Mutation Assay* compared to Next Generation Sequencing, shows **high sensitivity** and **ease of use** combined with **fast turnaround time** for the testing of 49 relevant EGFR mutations in 2 ml of NSCLC plasma samples.

- Thirty-four mutations were detected by NGS and confirmed by the Idylla™ ctEGFR prototype assay.
- An additional 8 mutations were detected by the Idylla™ ctEGFR prototype assay and confirmed by Cobas.

MUTATIONS DETECTED

ldylla™ 42

NGS 34



COMPLEMENT YOUR TISSUE TESTING

Obtaining samples for biomarker testing of sufficient quantity and quality is known to be a major challenge in several cancer types including lung cancer:

- Tissue samples might be too small
- · Tumor content might be too low
- Tumor might be hard to reach

Especially for these cases, testing plasma samples can be a rapid and cost-effective alternative and a valuable complement to tissue testing.

LIQUID BIOPSY WORKFLOW IDYLLA™ ctEGFR MUTATION ASSAY



Contact details Biocartis NV Generaal de Wittelaan 11B 2800 Mechelen - Belgium +32 15 632 888 www.biocartis.com

customerservice@biocartis.com



Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis trademark and logo and the Idylla trademark and Iogo are used trademarks owned by Biocartis. Idylla™ platform is CE-marked IVD in Europe. Idylla™ ctEGFR Mutation Assay is available for Research Use Only (RUO), not for use in diagnostic procedures. Idylla™ is available for sale in EU, USA and some other countries. Please check availability with the local Biocartis sales representative.